CME Information
Target audience
This CME-certified activity has been developed for gastroenterologists who have an interest in optimizing the management of patients with Crohn's disease.
Learning objectives:
Upon completion of this activity participants should be able to:
- Discuss how the latest data presented at DDW 2007 will advance current clinical practice in the management of Crohn’s disease
- Explain how to integrate expert clinical opinion with the best available evidence to achieve a new level of best practice.
Syllabus disclosure statement
In direct response to the September 2004 Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during this CME/CE activity.
The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation.
| Faculty Name | Company | Relationship |
| Stephen B. Hanauer | Abbott Laboratories, Centocor, Inc., Elan Pharmaceuticals, Inc., PDL BioPharma, UCB, Inc. | Advisory Board |
| Abbott Laboratories, Centocor, Inc., UCB, Inc. | Honoraria | |
Bret A. Lashner |
Abbott Laboratories, Elan Pharmaceuticals, Inc., Prometheus Pharmaceuticals, Inc., Shire Pharmaceuticals, UCB, Inc. | Advisory Board |
| Abbott Laboratories, Procter and Gamble Pharmaceuticals, Prometheus Pharmaceuticals, Inc., Shire Pharmaceuticals | Speakers Bureau |
|
Corey A. Siegel |
Abbott Laboratories, UCB, Inc. |
Advisory Board |
Elan Pharmaceuticals, Inc. |
Consultant |
|
| Prometheus Laboratories, Inc., Salix Pharmaceuticals, Shire Pharmaceuticals | Speakers Bureau |
The planners, managers and anyone in a position to control the content of CME activities are also required to report any conflicts of interest. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee.
| Name of Planner or Manager | Company and Relationship |
| Samantha Mattiucci, PharmD, CME Consultants | Nothing to disclose |
| Joyce M. Anderson, Project Director, CME Consultants | Nothing to disclose |
| Sarah Diffen, Senior Project Manager, Strategic Consultants International | Nothing to disclose |
| Alison Howe, Managing Director, Strategic Consultants International | Nothing to disclose |
Accreditation Statement
CME Consultants, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Consultants designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some of the agents mentioned. Please consult the full prescribing information for full disclosure of approved uses.
Off-label treatments for Crohn’s disease: Certolizumab pegol, natalizumab.
This activity should take approximately 90 minutes to complete, including the time to take the test and complete the evaluation.
Date of original release: September 4, 2007Valid for credit through: September 4, 2008